摘要 |
A heterocyclic compound of the formula (I): wherein B<SUP>1 </SUP>is -C(R<SUP>2</SUP>)- or -N-; R<SUP>1</SUP>' is H, etc.; one of R<SUP>1 </SUP>and R<SUP>2 </SUP>is -Z<SUP>1</SUP>-Z<SUP>2</SUP>-Z<SUP>3</SUP>-R<SUP>5 </SUP>wherein Z<SUP>1 </SUP>and Z<SUP>3 </SUP>are independently single bond, optionally substituted alkylene, etc.; Z<SUP>2 </SUP>is single bond, optionally substituted alkylene, etc.; R<SUP>1 </SUP>is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R<SUP>1 </SUP>and R<SUP>2 </SUP>is H; -A<SUP>1</SUP>- is -C(-Y)-C(-R<SUP>A</SUP>)-C(-R<SUP>3</SUP>)-C(-R<SUP>4</SUP>)-, etc. wherein Y is OH, etc.; R<SUP>A </SUP>is -COR<SUP>7 </SUP>wherein R<SUP>7 </SUP>is OH, etc.; one of R<SUP>3 </SUP>and R<SUP>4 </SUP>is carboxy, etc., and the other of R<SUP>1 </SUP>and R<SUP>2 </SUP>is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.
|